Acute bronchitis in children
Abstract: Umckaloabo®, an ethanolic extract from the roots of Pelargonium reniforme/and/or P. sidoides with antiinfectious properties, has been used successfully since years for the treatment of respiratory tract and ENT infections. The objective of our multicenter, non-randomized observational study was to investigate the specific efficacy and tolerability of Umckaloabo® in the treatment of acute bronchitis in children. Data were analyzed from a total of 742 patients in the age between 0 and 12 years (mean age 4 ± 3 years). Therapy with Umckaloabo® resulted in 90.2% of the patients either to complete remission or to significant improvement of the complaints. In the course of the maximum 2-week treatment, the objective severity score for bronchitic symptoms decreased from 6.0 ± 3.0 points to 1.4 ± 2.1 points (p < 0.001). Corresponding to the objective severity score for bronchitic Symptoms the rate of children suffering from loss of appetite, vomiting, diarrhea, headache, and fever decreased. Concomitant clinical symptoms disappeared within three days in the mean. Considering the therapeutical benefit the physicians declared that they would have prescribed Umckaloabo® again in 97.2 % of the cases. Tolerability was rated by the physicians to be very good and good in 9 4,9 % of the patients. Only 8 patients (1.1 %) experienced adverse events which possibly or probably were related to the medication. Due to the extremely low rate of side effects and the high rate of efficiency as well as to the rapid onset of the therapeutic effect, Umckaloabo® proves to be a safe measure for the treatment of acute bronchitis especially in pediatric practice. The excellent gustatory acceptance enhances the compliance of the young critical patients and contributes decisively to the therapeutic success of the drug.
Keyword(s): Acute bronchitis